Your browser is no longer supported. Please, upgrade your browser.
EPZM Epizyme, Inc. monthly Stock Chart
Epizyme, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own0.60% Shs Outstand101.10M Perf Week10.50%
Market Cap1.33B Forward P/E- EPS next Y-2.12 Insider Trans-13.02% Shs Float82.79M Perf Month4.91%
Income-201.90M PEG- EPS next Q-0.60 Inst Own96.90% Short Float11.66% Perf Quarter-29.62%
Sales13.80M P/S96.48 EPS this Y-12.00% Inst Trans1.45% Short Ratio8.52 Perf Half Y-11.42%
Book/sh2.54 P/B5.22 EPS next Y10.20% ROA-49.30% Target Price- Perf Year18.92%
Cash/sh3.21 P/C4.13 EPS next 5Y38.00% ROE-72.70% 52W Range9.73 - 27.82 Perf YTD-46.10%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-53.70% 52W High-55.39% Beta1.76
Dividend %- Quick Ratio11.20 Sales past 5Y-10.50% Gross Margin88.20% 52W Low27.48% ATR0.67
Employees203 Current Ratio11.60 Sales Q/Q-57.60% Oper. Margin- RSI (14)45.11 Volatility6.21% 5.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.40% Profit Margin- Rel Volume1.10 Prev Close13.26
ShortableYes LT Debt/Eq0.32 EarningsAug 04 BMO Payout- Avg Volume1.13M Price12.41
Recom1.70 SMA20-2.15% SMA50-6.70% SMA200-30.31% Volume331,542 Change-6.41%
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Mar-10-16Reiterated Mizuho Buy $26 → $20
Sep-08-20 06:30AM  
Sep-03-20 11:31AM  
Aug-18-20 01:05PM  
Aug-05-20 11:29AM  
Aug-04-20 05:00PM  
Jul-28-20 06:30AM  
Jul-16-20 06:31PM  
Jun-28-20 09:31AM  
Jun-20-20 07:57AM  
Jun-19-20 10:19AM  
Jun-18-20 01:31PM  
Jun-17-20 01:56PM  
Jun-16-20 07:09AM  
Jun-03-20 11:30AM  
May-26-20 12:55PM  
May-14-20 09:22AM  
May-13-20 05:12PM  
May-07-20 10:51AM  
May-05-20 09:11AM  
May-04-20 07:00PM  
Apr-27-20 12:32PM  
Apr-26-20 10:02AM  
Apr-19-20 07:02AM  
Apr-08-20 06:56PM  
Mar-25-20 11:30AM  
Mar-20-20 06:30AM  
Mar-06-20 03:41AM  
Feb-26-20 06:39AM  
Feb-25-20 12:09PM  
Feb-24-20 07:45AM  
Feb-23-20 06:38PM  
Feb-20-20 08:42AM  
Feb-19-20 09:21AM  
Feb-18-20 06:30AM  
Feb-14-20 08:23AM  
Feb-12-20 06:55AM  
Feb-06-20 05:50PM  
Feb-05-20 11:52AM  
Jan-31-20 05:50PM  
Jan-29-20 09:59AM  
Jan-24-20 12:00PM  
Jan-23-20 06:07PM  
Jan-22-20 11:30AM  
Jan-21-20 09:26AM  
Jan-20-20 02:04PM  
Jan-17-20 08:45AM  
Jan-09-20 04:47PM  
Jan-08-20 12:00PM  
Jan-07-20 10:26AM  
Jan-06-20 06:30AM  
Dec-30-19 09:24AM  
Dec-26-19 10:38AM  
Dec-24-19 08:15AM  
Dec-23-19 10:18AM  
Dec-19-19 10:02AM  
Dec-18-19 05:27PM  
Dec-17-19 09:11AM  
Dec-16-19 12:00PM  
Dec-15-19 03:49PM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-10-19 07:56AM  
Dec-07-19 10:05AM  
Dec-06-19 07:39AM  
Dec-03-19 03:18PM  
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beaulieu JosephCorporate ControllerSep 02Sale12.885436,9945,958Sep 03 09:30 PM
MOTT DAVID MDirectorJun 26Buy16.0362,019994,16582,601Jun 26 07:12 PM
Beaulieu JosephCorporate ControllerJun 26Sale16.153175,1204,838Jun 30 09:04 AM
Bazemore Robert BPresident & CEOJun 26Sale16.154,77377,084250,098Jun 30 09:01 AM
Agarwal ShefaliChief Medical OfficerJun 26Sale16.151,80529,15178,611Jun 30 08:56 AM
TOMBESI PAOLOChief Financial OfficerJun 26Sale16.151,80529,15121,942Jun 30 08:57 AM
Ros MatthewSee RemarksJun 26Sale16.152,72844,05757,507Jun 30 08:54 AM
Bazemore Robert BPresident & CEOJun 18Option Exercise8.9810,00089,800264,371Jun 22 07:36 PM
Ros MatthewSee RemarksJun 18Option Exercise9.47112,0031,060,669120,449Jun 22 07:31 PM
Bazemore Robert BPresident & CEOJun 18Sale22.0020,000440,000244,371Jun 22 07:36 PM
Ros MatthewSee RemarksJun 18Sale21.24112,0032,378,44451,798Jun 22 07:31 PM
Beaulieu JosephCorporate ControllerMar 25Sale15.282123,2394,961Mar 26 09:11 PM
TOMBESI PAOLOChief Financial OfficerMar 25Sale15.281,24318,99315,437Mar 26 09:01 PM
Ros MatthewSee RemarksMar 25Sale15.281,24318,99351,798Mar 26 09:01 PM
Agarwal ShefaliChief Medical OfficerMar 25Sale15.281,24318,99371,991Mar 26 09:00 PM
Bazemore Robert BPresident & CEOMar 25Sale15.283,28550,195254,371Mar 26 09:00 PM
Allen Andrew RDirectorMar 16Option Exercise9.3312,500116,62512,500Mar 18 04:30 PM
Beaulieu JosephCorporate ControllerMar 03Sale22.1899622,0913,617Mar 05 06:52 PM
Bazemore Robert BPresident & CEOJan 27Sale20.446,074124,15384,668Jan 27 09:17 PM
Agarwal ShefaliChief Medical OfficerJan 27Sale20.442,63053,75758,803Jan 27 09:19 PM
Agarwal ShefaliChief Medical OfficerJan 24Sale24.641,84345,41261,433Jan 27 09:19 PM
Bazemore Robert BPresident & CEOJan 24Sale24.623,00273,90990,742Jan 27 09:17 PM
Ros MatthewSee RemarksJan 24Sale24.641,84745,51042,185Jan 27 09:18 PM
Beaulieu JosephCorporate ControllerJan 24Sale24.633308,1281,042Jan 27 09:16 PM